A Comprehensive Analysis of Metabolomics and Transcriptomics Reveals Novel Biomarkers and Mechanistic Insights on Lorlatinib Crosses the Blood-Brain Barrier
Authors:
Open Access
- 23 August 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
Of late, lorlatinib has played an increasingly pivotal role in the treatment of brain metastasis from non-small cell lung cancer. However, its pharmacokinetics in the brain and the mechanism of entry are still controversial. The purpose of this study was to explore the mechanisms of brain penetration by lorlatinib and identify potential biomarkers for the prediction of lorlatinib concentration in the brain. Detection of lorlatinib in lorlatinib-administered mice and control mice was performed using liquid chromatography and mass spectrometry. Metabolomics and transcriptomics were combined to investigate the pathway and relationships between metabolites and genes. Multilayer perceptron was applied to construct an artificial neural network model for prediction of the distribution of lorlatinib in the brain. Nine biomarkers related to lorlatinib concentration in the brain were identified. A metabolite-reaction-enzyme-gene interaction network was built to reveal the mechanism of lorlatinib. A multilayer perceptron model based on the identified biomarkers provides a prediction accuracy rate of greater than 85%. The identified biomarkers and the neural network constructed with these metabolites will be valuable for predicting the concentration of drugs in the brain. The model provides a lorlatinib to treat tumor brain metastases in the clinic.Keywords
This publication has 57 references indexed in Scilit:
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant MutationsJournal of Medicinal Chemistry, 2014
- The DAO Gene Is Associated with Schizophrenia and Interacts with Other Genes in the Taiwan Han Chinese PopulationPLOS ONE, 2013
- Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brainProceedings of the National Academy of Sciences, 2012
- The EYA Tyrosine Phosphatase Activity Is Pro-Angiogenic and Is Inhibited by BenzbromaronePLOS ONE, 2012
- Phosphatidylcholine hydroperoxide promotes VEGF-induced angiogenesis in endothelial cells and rat aorta ring culturesBiochimica et Biophysica Acta (BBA) - General Subjects, 2011
- Potential use of tight junction modulators to reversibly open membranous barriers and improve drug deliveryBiochimica et Biophysica Acta (BBA) - Biomembranes, 2009
- Discovery of tight junction modulators: significance for drug development and deliveryDrug Discovery Today, 2008
- CYP4B1: An Enigmatic P450 at the Interface between Xenobiotic and Endobiotic MetabolismDrug Metabolism Reviews, 2006
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004
- P-Glycoprotein, a gatekeeper in the blood–brain barrierAdvanced Drug Delivery Reviews, 1999